Tüdőrák: vizsgálatok itt: Japán

In Japán 135 Also abroad 2746

135 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.

1. fázisNot yet taking people in Japán
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
Where
Shizuoka, Tokyo
Életkor
18 év and over
People
370 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07928258 · EU 2026-526553-33-00
3. fázisTaking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Akashi, Fukushima, Fukuyama-shi, Gifu, Hamamatsu, Hidaka, Hirakata, Kashihara, Kashiwa, Kitakyushu, Koto, Kurashiki, Kurume, Nagaizumi-cho,Sunto-gun, Nakamura-ku,Nagoya, Nankoku, Natori-shi, Niigata, Osaka, Sagamihara, Sakai, Sapporo, Sendai, Yokohama
Életkor
18 év and over
People
1000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
3. fázisTaking people
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Where
Chiba, Chūō, Fukuoka, Fukushima, Hirakata, Hiroshima, Kashiwa, Kawasaki, Kitakyushu, Okayama, Osaka, Sakai, Shimotsuga-gun, Shinjuku, Sunto-gun, Wakayama, Yokohama
Életkor
18 év and over
People
680 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00
2. fázisTaking people
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Where
Osaka, Sakai, Tokyo, Chuo-ku
Életkor
18 év and over
People
60 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07486817 · EU 2025-523567-38-00
3. fázisTaking people
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Where
Fukushima, Kitakyushu, Yamagata
Életkor
18 év and over
People
876 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Gifu, Hiroshima, Hyōgo, Ōita
Életkor
18 év and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
3. fázisTaking people
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Where
Akashi, Bunkyo-ku, Fukuoka, Hirakata, Hiroshima, Nagaizumi-cho,Sunto-gun, Natori-shi, Niigata, Sakai, Sapporo, Tokyo, Yokohama
Életkor
18 év and over
People
356 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566052 · EU 2025-524079-22-00
No phaseNot yet taking people in Japán
Real-world Outcome of Zongertinib in Japan (J-HERZ)
Where
Tokyo
Életkor
18 év and over
People
300
Run by
Boehringer Ingelheim
See details and how to joinNCT07926308
1/2. fázisTaking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Kanagawa, Okayama, Osaka, Shizuoka, Tokyo, Wakayama
Életkor
12 év and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
3. fázisTaking people
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Where
Akashi, Chuo Ku, Hidaka, Hirakata-shi, Kanazawa, Kashihara-shi, Kashiwa-shi, Koto-Ku, Kyoto, Matsuyama, Nagaizumi-chō, Nagoya, Niigata, Osakasayama-Shi, Sagamihara, Sapporo, Sendai, Toyoake-shi, Wakayama, Yokohama
Életkor
18 év and over
People
590 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00
1/2. fázisTaking people
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Where
Chiba, Osaka, Tokyo, Wakayama
Életkor
18 év and over
People
320 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00
3. fázisTaking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Aichi, Fukuoka, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Miyagi, Niigata, Okayama, Osaka, Sendai, Shizuoka, Tokyo, Wakayama
Életkor
18 év and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
3. fázisTaking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Akashi, Beppu-shi, Bunkyo-ku, Fukuoka, Kiyose, Kochi, Kure, Kurume, Kyoto, Nagaizumi-chō, Okayama, Ōmura, Osaka, Sakai, Sendai, Suita, Tsu
Életkor
18 év and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
3. fázisTaking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Bunkyo Ku, Fukuoka, Hamamatsu, Hidaka, Hirakata, Kobe, Nagoya, Nishinomiya, Okayama, Sagamihara, Sakai, Sendai, Yokohama
Életkor
18 év and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
1/2. fázisTaking people
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Where
Akashi, Fukushima, Hidaka, Koto, Nagaizumi-chō, Ōta, Sapporo, Shinjuku-ku, Yamagata
Életkor
18 év and over
People
952 worldwide
Run by
Genmab
See details and how to joinNCT05579366
3. fázisTaking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Asahikawa, Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kasama, Kashiwa, Kobe, Kōtō City, Kyoto, Matsuyama, Nagaizumi-cho,Sunto-gun, Nagasaki, Nagoya, Natori, Niigata, Okayama, Sakai, Sapporo, Ube, Utsunomiya, Wakayama, Yokohama, Yonago
Életkor
18 év and over
People
1264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
1. fázisTaking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Shizuoka, Tokyo
Életkor
18 év and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
3. fázisTaking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Bunkyo-ku, Fukuoka, Himeji, Hirakata, Kashiwa, Kitaadachi, Kobe, Nagoya, Niigata, Osaka, Sagamihara, Sakai, Sapporo, Sendai, Ube, Yonago
Életkor
18 év and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
1. fázisTaking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Chūōku, Kashiwa, Chiba, Kōtō City, Nagoya
Életkor
18 év and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
1/2. fázisTaking people
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Where
Kashiwa, Osakasayama-Shi, Tsukiji
Életkor
18 év and over
People
675 worldwide
Run by
BlossomHill Therapeutics
See details and how to joinNCT06706076
3. fázisTaking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kashiwa, Kobe, Kōtō City, Kyoto, Nagaizumi-cho,Sunto-gun, Nagoya, Natori, Niigata, Sakai, Sapporo, Wakayama, Yokohama, Yonago
Életkor
18 év and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
2. fázisTaking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Chuo Ku
Életkor
18 év and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
2. fázisFut, nem toboroz
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Where
Himeji, Matsusaka, Niigata, Shizuoka, Tokyo, Wakayama
Életkor
18 év and over
People
520 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00
3. fázisTaking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Bunkyo, Fukuoka, Himeji, Hirakata, Hirosaki, Kashiwa, Kawasaki, Koto, Kumamoto, Kurume, Matsusaka, Matsuyama, Niigata, Osaka, Ōta, Ōta-ku, Sendai, Shimotsugagun, Shinjuku, Shiwa-gun, Suntogun, Takatsuki, Toyoake, Ube, Ureshino, Yokohama
Életkor
18 év and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
2. fázisTaking people
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Where
Chūō, Kyoto, Nagoya, Sagamihara, Saitama, Sakai, Tokyo, Yokohama
Életkor
18 év and over
People
240 worldwide
Run by
Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00